MANGOCEUTICALS INC

Company Overview

Mangoceuticals, Inc. (MangoRx) is a telehealth-first men’s wellness platform that routes consumer requests to third‑party telemedicine providers and outsources compounding, fulfillment and distribution to a related‑party pharmacy (Epiq Scripts). Its product suite targets erectile dysfunction, hair loss, hormone balance, weight management and an FDA‑approved oral testosterone therapy marketed under a partner agreement; the company also holds acquired IP (respiratory prevention tech and mushroom‑derived nutraceuticals) and distribution/licensing agreements for international expansion. The business is platform‑driven, subscription‑focused and highly dependent on the 503A compounding exemption, state telehealth/pharmacy licensing, the Marius marketing arrangement and the exclusive pharmacy services contract. Management reports modest revenues, persistent net losses and a precarious liquidity position that requires near‑term financing to continue operations and execute a relaunch and commercialization plans.

Executive Compensation Practices

Compensation at MangoRx reflects a small, cash‑constrained healthcare services company: base salaries have risen modestly while non‑cash, equity‑based pay is a dominant component—stock‑based compensation was material in 2024 (~$2.36M) and increased further in 2025 through issuance of restricted shares for services. Given limited cash flow, management incentives are likely weighted toward equity awards and milestone‑based payouts tied to subscription growth, platform relaunch success, commercialization milestones (e.g., Dermytol) and IP/clinical milestones (Phase II respiratory trial outcomes). The company’s financial disclosures call out complex valuation judgments (Black‑Scholes inputs) and patent amortization, so reported compensation expense and realized value to executives may diverge materially from GAAP grant values. Board and investors should expect ongoing use of equity, convertible instruments and service‑share issuance as primary retention and compensation levers.

Insider Trading Considerations

Insider activity at MangoRx should be evaluated in the context of frequent dilutive financings, convertible note conversions, warrant resets/anti‑dilution mechanics and equity‑line draws—events that historically coincide with clustered insider issuances, conversions or sales. Closely monitor Form 4 filings for large option grants, restricted share issuances for services, note conversions and insider sales tied to financing closings; related‑party relationships (Epiq Scripts) and rescinded IP deals increase the likelihood of non‑routine insider transactions. Regulatory and clinical milestones (503A guidance, state telehealth rules, Phase II trial readouts) are material events for this issuer, so executives trading around such disclosures could raise governance and disclosure risk; look also for adoption of 10b5‑1 plans or trading blackout policies that would affect the timing and interpretation of insider trades.